Global InformationTengion information
| Company type | Public |
|---|---|
Traded as | Expert Market: TNGNQ |
| Industry | Biotechnology |
| Founded | 2003 |
| Headquarters | Winston-Salem, North Carolina , United States |
Key people | David I. Scheer (Chairman) John L. Miclot |
Number of employees | 25 |
| Website | www |
Tengion, Inc. is an American development-stage regenerative medicine company founded in 2003 with financing from J&J Development Corporation, HealthCap and Oak Investment Partners, which is headquartered in Winston-Salem, North Carolina.[1] Its goals are discovering, developing, manufacturing and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues, to address unmet medical needs in urologic, renal, gastrointestinal, and vascular diseases and disorders. The company creates these human neo-organs from a patient’s own cells or autologous cells, in conjunction with its Organ Regeneration Platform.
The company declared Chapter 7 bankruptcy in December 2014, and it, along with its assets and tissue engineering samples, have been bought back by its creditors and former executives as of March 2015. The purchase was expedited, so that time-sensitive research can continue.[2]
- ^ Health Care Sector Wrap Archived 2012-08-18 at the Wayback Machine, FOX BUSINESS (August 14, 2012)
- ^ Craver, Richard (March 6, 2015). "Bankruptcy Court approves offer to buy Tengion". Winston-Salem Journal. Retrieved June 3, 2024.